Day One Biopharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Day One Biopharmaceuticals is Jeremy Bender, benoemd in Sep2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.91M, bestaande uit 9.4% salaris en 90.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.69% van de aandelen van het bedrijf, ter waarde $ 23.26M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 3.7 jaar.
Belangrijke informatie
Jeremy Bender
Algemeen directeur
US$6.9m
Totale compensatie
| Percentage CEO-salaris | 9.4% |
| Dienstverband CEO | 4.2yrs |
| Eigendom CEO | 1.7% |
| Management gemiddelde ambtstermijn | 3.2yrs |
| Gemiddelde ambtstermijn bestuur | 3.7yrs |
Recente managementupdates
Recent updates
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$84m |
| Jun 30 2024 | n/a | n/a | -US$167m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$7m | US$647k | -US$189m |
| Sep 30 2023 | n/a | n/a | -US$175m |
| Jun 30 2023 | n/a | n/a | -US$166m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$5m | US$610k | -US$142m |
| Sep 30 2022 | n/a | n/a | -US$124m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$183m |
| Dec 31 2021 | US$20m | US$523k | -US$171m |
| Sep 30 2021 | n/a | n/a | -US$183m |
| Jun 30 2021 | n/a | n/a | -US$167m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$3m | US$142k | -US$41m |
Compensatie versus markt: De totale vergoeding ($USD 6.91M ) Jeremy } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.37M ).
Compensatie versus inkomsten: De vergoeding van Jeremy is gestegen terwijl het bedrijf verliesgevend is.
CEO
Jeremy Bender (53 yo)
4.2yrs
Tenure
US$6,913,959
Compensatie
Dr. Jeremy Bender, Ph D., M.B.A. serves as Chief Executive Officer, President and Director of Day One Biopharmaceuticals, Inc. since September 2020. He serves as President, Chief Executive Officer and Dire...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$6.91m | 1.69% $ 23.3m | |
| Co-Founder and Head of R&D | 6.8yrs | US$2.49m | 2.04% $ 28.0m | |
| COO, CFO & Secretary | 3.8yrs | US$3.55m | 0.23% $ 3.2m | |
| General Counsel and Chief Compliance Officer | 2.1yrs | US$2.77m | 0.027% $ 366.7k | |
| Chief Technology Officer | no data | geen gegevens | geen gegevens | |
| Chief People Officer | 3.2yrs | geen gegevens | geen gegevens | |
| Chief Development Officer | no data | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | less than a year | geen gegevens | geen gegevens |
3.2yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DAWN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$6.91m | 1.69% $ 23.3m | |
| Independent Director | 4.2yrs | US$350.75k | 0.072% $ 984.7k | |
| Board Observer | no data | geen gegevens | geen gegevens | |
| Chairman of the Board & Lead Independent Director | 2.2yrs | US$383.38k | 0% $ 0 | |
| Board Observer | no data | geen gegevens | geen gegevens | |
| Independent Director | less than a year | geen gegevens | 0% $ 0 | |
| Independent Director | 3.3yrs | US$342.88k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$342.88k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$351.75k | 0.040% $ 551.5k | |
| Independent Director | 3.8yrs | US$352.50k | 0.057% $ 780.6k | |
| Independent Director | less than a year | geen gegevens | 0% $ 0 |
3.7yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DAWN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).